nav-left cat-right
cat-right

Analyzing the Winners and Losers in the Growth of ...

Success of Delivery Device Developers in Solving Formulation Limitations a Key Factor according to Greystone Research Associates (Amherst, NH) – As patients live longer and the prevalence and incidence of chronic ailments increase across the general population, drug developers and their delivery device partners are adapting to address what will become a significant market opportunity. Chronic conditions require drug...

NIH lays out plan to work exome data into clinical...

Having seen the cost of exome sequencing tumble in recent years, the National Institutes of Health (NIH) has decided now is the time to jump-start its genomic medicine program. The upshot is more clinical research programs will soon have access to exome sequencing capabilities and NIH support with management of the resulting data. NIH has branded the two-year plan the Clinical Center Genomics Opportunity (CCGO) and committed...

J&J gambles $12.5M in rare Big Pharma bet on ...

Later this week a little biotech named Capricor Therapeutics is set to begin a Phase II study of its new stem cell therapy with about $20 million in support from the California Institute for Regenerative Medicine (CIRM). And this morning Johnson & Johnson ($JNJ) is stepping up with a $12.5 million upfront to buy itself an option and a front-row seat on the program–marking a rare Big Pharma gamble on a field that is...

U.S. domination of global biomedical R&D slip...

Big Pharma’s decision to shift more of its R&D resources to Asia over the past few years has helped spur a subtle but significant erosion of the U.S.’s traditional dominance in the field. New research from the University of Michigan Health System shows that the U.S. share of the global biomedical R&D business declined to 45%–from 51%–between 2007 and 2012. And while Europe stayed steady at 29%,...

Celgene, Lilly back $100M VC for biotech startups ...

Three big players in the life sciences industry–Celgene ($CELG), Eli Lilly ($LLY) and GE Ventures–are chipping in to help fund a $100 million venture fund that will be used to launch up to 20 new biotech companies in New York City, adding some fuel to a small but growing fire of R&D efforts in the Big Apple. The Bloomberg administration took the lead on this project, according to The Wall Street Journal,...

Aviir opens new cardiac clinical lab in Irvine

Aviir has launched a new clinical laboratory in Irvine in an effort to improve cardiovascular disease prevention and management of related conditions, including diabetes. The 16,700-square-foot facility currently houses 22 employees, and the medical firm plans to grow that number to 115 over the next year. More than half of those staffers will be proficient in laboratory sciences and information technology. They will...
Page 2 of 1912345...10...Last »